Eikon Therapeutics Inc

Research Eikon Therapeutics Inc (EIKN) on Bullrun: market cap USD 679.57M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerEIKN
ExchangeNASDAQ
CountryUnited States
SectorHealthcare
IndustryBiotechnology
CurrencyUSD
Market capUSD 679.57M
Financial periodQ1 2026
RevenueUSD 0
Net income-USD 82.96M
Free cash flow-USD 90.06M

Valuation Snapshot

latest market cap is USD 679.57M.

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-08-25	USD 679.57M	n/a	n/a	n/a

About Eikon Therapeutics Inc

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant;

Related stock research

United States stocks United States Healthcare stocks A-Z stock index

Other Healthcare stocks

Adicet Bio Inc (1IJ) Cartesian Therapeutics, Inc. (1S70) QUOIN PHARMACEUT.ADR5000 (2EB0) Aardvark Therapeutics Inc (AARD) Abeona Therapeutics Inc (ABEO) Acumen Pharmaceuticals Inc (ABOS) Absci Corp (ABSI) Arbutus Biopharma Corp (ABUS) ABVC BioPharma Inc (ABVC) Acadia Pharmaceuticals Inc (ACAD) Adicet Bio Inc (ACET) Achieve Life Sciences Inc (ACHV)

Frequently asked questions

What is Eikon Therapeutics Inc's market cap?

Eikon Therapeutics Inc's market capitalization is USD 679.57M.

What does Eikon Therapeutics Inc do?

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.